Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Literature
1.
Simone F, Luo RT, Polak PE, Kaberlein JJ, Thirman MJ (2003) ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties. Blood 101:2355–2362CrossRefPubMed
2.
Xiao W, Zhang Q, Jiang F, Pins M, Kozlowski JM, Wang Z (2003) Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer. Cancer Res 63:4698–4704PubMed
3.
Imai K, Yamamoto H (2008) Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29:673–680CrossRefPubMed
4.
Oh HR, An CH, Yoo NJ, Lee SH (2015) Frameshift mutations of MUC15 gene in gastric and its regional heterogeneity in gastric and colorectal cancers. Pathol Oncol Res 21:713–718CrossRefPubMed
5.
Liu JX, Zhang D, Xie X, Ouyang G, Liu X, Sun Y, Xiao W (2013) Eaf1 and Eaf2 negatively regulate canonical Wnt/β-catenin signaling. Development 140:1067–1078CrossRefPubMed
Metadata
Title
Candidate Tumor Suppressor Gene EAF2 is Mutated in Colorectal and Gastric Cancers
Publication date
01-04-2019
Published in
Pathology & Oncology Research / Issue 2/2019
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-0461-1

Other articles of this Issue 2/2019

Pathology & Oncology Research 2/2019 Go to the issue

Original Article

Sarcomas of the Oral and Maxillofacial Region: Analysis of 26 Cases with Emphasis on Diagnostic Challenges

Original Article

Gene Promoter Methylation in Endometrial Carcinogenesis

Original Article

Approach the Invasive Potential with Hurthle Cell Tumors of Thyroid

Original Article

Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis

Letter to the Editor

The Diagnostic Dilemma of Epithelial Marker Expression in Glioblastoma

Letter to the Editor

Association of Schistosomiasis with Cervical Cancer in Togo: the Consequence of this Association
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits